Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells

Breast Cancer Research and Treatment

Volumn 81, Issue 1, 2003, Pages 81-93

  Hutcheson, Iain R ^a   Knowlden, Janice M ^a   Madden, Tracie Ann ^a   Barrow, Denise ^a   Gee, Julia M W ^a   Wakeling, Alan E ^b   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

c erbB2; Epidermal growth factor receptor; Fulvestrant; Mitogen activated protein kinase; Oestrogen receptor; Tamoxifen resistance; Transforming growth factor alpha

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FULVESTRANT; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAMOXIFEN;

EID: 0041736202     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025484908380     Document Type: Article

References (63)

1. Howell A, Defriend D, Anderson E: Mechanisms of response and resistance to endocrine therapy for breast cancer and the development of new treatments. Rev Endocr-Related Cancer 43: 5-21, 1993
2. Osborne CK, Fuqua SA: Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 32: 49-55, 1994
3. Clarke R, Leonessa F, Welch JN, Skaar TC: Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53: 25-71, 2001
4. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118-121, 1992
5. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW: Relationship between EGF-R, c-erbB2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A: 1018-1023, 1993
6. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW: Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy. Breast Cancer Res Treat 29: 117-125, 1994
7. Daly RJ: Take your partners, please-signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors 16: 255-263, 1999
8. Olayioye MA, Neve RM, Lane HA, Hynes N: The erbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000
9. Long B, McKibben BM, Lynch M, van den Berg HW: Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br J Cancer 65: 865-869, 1992
10. El-Zarruk AA, van den Berg HW: The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase. Cancer Lett 142: 185-193, 1999
11. van Agthoven TT, van Agthoven TL, Portengen H, Foekens JA, Dorssers LC: Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52: 5082-5088, 1992
12. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent tamoxifen-resistant tumorigenic growth of MCF7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95, 1992
13. Miller DL, El-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG: Emergence of MCF7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Diff 5: 1263-1274, 1994
14. Liu Y, El-Ashry D, Chen D, Ding IY, Kern FG: MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34: 97-117, 1995
15. Kurokawa H, Lenferink AEG, Simpson JF, Piscane PI, Sliwkowski MX, Forbes JT, Arteaga CL: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60: 5887-5894, 2000
16. Schlessinger J: Cell Signaling by receptor tyrosine kinases. Cell 103: 211-225, 2000
17. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U: Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer (Pred Oncol) 89: 384-388, 2000
18. Gee JMW, Robertson JFR, Ellis IO, Nicholson RI: Phosphorylation of ERK1/ 2 mitogen activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95: 247-254, 2001
19. Coutts AS, Murphy LC: Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 58: 4071-4074, 1998
20. Shim W-S, Conaway M, Masamura S, Yue W, Wang J-P, Kumar R, Santen RJ: Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinol 141: 396-405, 2000
21. El-Ashry D, Miller DL, Kharbanda S, Lippman ME, Kern FG: Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15: 423-435, 1997
22. Donovan JCH, Milic A, Slingerland JM: Constitutive MEK/MAPK activation leads to p27Kipl deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 276: 40888-40895, 1997
23. McClelland RA, Barrow D, Madden T, Dutkowski CM, Pamment J, Knowlden J, Gee JMW, Nicholson RI: Enhanced epidermal growth factor receptor signalling in MCF7 breast cancer cells following long-term culture in the presence of the pure antioestrogen ICI 182,780 (Faslodex). Endocrinol 142: 2776-2788, 2001
24. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JMW, Harper ME, Barrow D, Wakeling AE, Nicholson RI: Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells. Endocrinol 144: 1032-1044, 2003
25. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SAW, Osborne CK: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26: 237-246, 1993
26. Brunner N, Frandesen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R: MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53: 3229-3232, 1993
27. Lykkesfeldt AE, Mogens MW, Briand P: Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAM R-1. Cancer Res 54: 1587-1595, 1994
28. Robertson JF: Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 73: 5-12, 1996
29. Dauvois S, Danielian PS, White R, Parker MG: Antiestrogen ICI164384 reduces cellular oestrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89: 4037-4041, 1992
30. Howell A, Osborne K, Wakeling A: Faslodex (ICI 182,780). Development of a novel 'pure' antiestrogen. Cancer 89: 817-825, 2000
31. Wakeling AE: Similarities and distinctions in the mode of action of different classes of antiestrogens. Endocr-Related Cancer 7: 17-28, 2000
32. Howell A, Robertson J: Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345: 989-990, 1995
33. Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, Sutcliffe FA, Walton P: Pharmacokinetics, pharmacological and anti-tumor effects of the specific anti-estrogen ICI 182,780 in women with advanced breast cancer. Br J Cancer 74: 300-308, 1996
34. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403, 2002
35. Coopman P, Garcia M, Brunner N, Derocq D, Clarke R, Rochefort H: Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells. Int J Cancer 56: 295-300, 1994
36. Hu XF, Veroni M, De Luise M, Wakeling A, Sutherland R, Watts CK, Zalcberg JR: Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer 55: 873-876, 1993
37. Knowlden JM, Gee JMW, Bryant S, McClelland RA, Manning DL, Mansel R, Ellis IO, Blamey RW, Robertson JF, Nicholson RI: Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. Clin Cancer Res 3: 2165-2172, 1997
38. Gee JMW, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI: Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994
39. Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC: Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res 57: 3723-3727, 1997
40. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, Melnerney EM: William M. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 44: 23-38, 1997
41. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494, 1995
42. Arnold SF, Obourn JD, Jaffe H, Notides AC: Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol 9: 24-33, 1995
43. Bunone G, Briand P-A, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15: 2174-2183, 1996
44. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74: 311-317, 2000
45. Webb P, Lopez GN, Uht RM, Kushner PJ: Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9: 443-456, 1995
46. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE: Progression of MCF7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Diff 7: 351-359, 1996
47. Johnston SRD, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumours with acquired tamoxifen resistance. Clin Cancer Res 5: 251-256, 1999
48. Porter W, Saville B, Hoivik D, Safe S: Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 11: 1569-1580, 1997
49. McPherson LA, Weigel RJ: AP2α and AP2γ: a comparison of binding site specificity and trans-activation of the estrogen receptor promoter and single site constructs. Nucl Acid Res 27: 4040-4049, 1999
50. Nicholson RI, McClelland RA, Robertson JFR, Gee JMW: Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr-Related Cancer 6: 373-387, 1999
51. Nicholson RI, Gee JMW: Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 82: 501-513, 2000
52. Berthois Y, Dong XF, Martin PM: Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. Biochem Biophys Res Commun 159: 126-131, 1989
53. Read LD, Keith Jr D, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947-3951, 1990
54. De Bortoli M, Dati C, Antoniotti S, Maggiora P, Sapei ML: Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells. J Steroid Biochem Mol Biol 43: 21-25, 1992
55. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME, Salomon DS: Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 2: 543-555, 1988
56. Saeki T, Cristiano A, Lynch MJ, Brattain M, Kim N, Normanno N, Kenney N, Ciardiello F, Salomon DS: Regulation by estrogen through the 5′-flanking region of the transforming growth factor alpha gene. Mol Endocrinol 5: 1955-1963, 1991
57. MacGregor Schafer J, Liu H, Levenson AS, Horiguchi J, Chen Z, Jordan VC: Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol 78: 41-50, 2001
58. Kumar V, Bustin SA, McKay IA: Transforming growth factor alpha. Cell Biol Int 19: 373-388, 1995
59. El-Ashry D, Chrysogelos SA, Lippman ME, Kern FG: Estrogen induction of TGF-alpha is mediated by an estrogen response element composed of two imperfect palindromes. J Steroid Biochem Mol Biol 59: 261-269, 1996
60. Wang D, Shin TH, Kudlow JE: Transcription factor AP-2 controls transcription of the human transforming growth factor-alpha gene. J Biol Chem 272: 14244-14250, 1997
61. Bjorge JD, Paterson AJ, Kudlow JE: Phorbol ester or epidermal growth factor (EGF) stimulates the concurrent accumulation of mRNA for the EGF receptor and its ligand transforming growth factor-alpha in breast cancer cell line. J Biol Chem 264: 4021-4027, 1989
62. Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1072: 129-157, 1991
63. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW: Transforming growth factor-alpha and endocrine sensitivity in breast cancer. Cancer Res 54: 1684-1689, 1994